Fallopian Tube Cancer

News

October 09, 2019

1 min read

Save

FDA grants fast track designation to navicixizumab for pretreated ovarian cancer

The FDA granted fast track designation to navicixizumab for the treatment of women with heavily pretreated high-grade ovarian, primary peritoneal or fallopian tube cancer.

Reminder from

Healio CME

You need

{credits} Credits

to reach your goal.

View Recommended CME

Reminder from

Healio CME

You're almost at

{percent}%

completed.

Keep it going!

View Recommended CME Edit Goal

Reminder from

Healio CME

Your deadline is here.

You need

{credits} Credits

to reach your goal.

View Recommended CME View goal